The focus of this present study is to investigate the effects of Resveratrol in combination with ERα agonist (E2), endocrine disrupter (BPA), and anti-estrogens (ICI and Tamoxifen) on the expression of p53 and ERα in T-47D breast cancer cells. The gene discussed is ESR1; the disease is breast carcinoma.